Report an error   

HERDIN Record #: PCHRD17032414450182 Submitted: 24 March 2017 Modified: 12 April 2017

A pilot study on single nucleotide polymorphisms of cathechol-O-methyltransferase (VAL158MET) and CYP2D6*10 (PRO34SER) and opioid use among cancer pain patients.

Francis O. Javier,
Antonio B. Yap,
Merlina L. Cabrera,
Lyde A. Magpantay,
Cynthia A. Mapua,
Maria Luisa G. Daroy,
Michael O. Baclig

See More

A hospital-based cross-sectional study was conducted to evaluate the association between catechol-0-methyltransferase (COMT) and CYP2D6*10 single nucleotide polymorphisms (SNPs) and opioid consumption among cancer pain patients. COMT and CYP2D6*10 genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). In this study, there was no association noted between COMT genotype and dosage of morphine. The odds of moderate to high morphine use among patients with Val/Val genotype were 1.78 times higher compared to those with Val/Met genotype. For CYP2D6*10 SNPs, there was no association noted when various doses of tramadol were compared against the three CYP2D6*10 genotypes (Homozygous C/C; Heterozygous C/T and Homozygous T/T). In conclusion, there was no association seen in both the pain candidate genes, COMT (Va1158Met) and CYP2D6*10 (Pro34Ser) and opioid use among cancer pain patients.

Publication Type
Publication Sub Type
Journal Article, Original
St. Luke's Healthcare Journal
Publication Date
July-December 2016
LocationLocation CodeAvailable FormatAvailability
Philippine Council for Health Research and Development Library Box No. 35 Fulltext Print Format

Copyright © One Window Project 2020. All rights reserved.